Cardiovascular diseases remain the most rapidly rising contributing factor of all-cause mortality and the leading cause of inpatient hospitalization worldwide, with costs exceeding $30 billion annually in North America. Cell surface and membrane-associated proteins play an important role in cardiomyocyte biology and are involved in the pathogenesis of many human heart diseases. In cardiomyocytes, membrane proteins serve as critical signaling receptors, Ca2+ cycling regulators, and electrical propagation regulators, all functioning in concert to maintain spontaneous and synchronous contractions of cardiomyocytes. Membrane proteins are excellent pharmaceutical targets due to their uniquely exposed position within the cell. Perturbations in cardiac membrane protein localization and function have been implicated in the progression and pathogenesis of many heart diseases. However, previous attempts at profiling the cardiac membrane proteome have yielded limited results due to poor technological developments for isolating hydrophobic, low-abundance membrane proteins. Comprehensive mapping and characterization of the cardiac membrane proteome thereby remains incomplete. This review will focus on recent advances in mapping the cardiac membrane proteome and the role of novel cardiac membrane proteins in the healthy and the diseased heart. Listen to this article's corresponding podcast at https://ajpheart.podbean.com/e/membrane-proteomic-profiling-of-the-heart/ .
Rationale: Interstitial lung abnormalities (ILAs) are incidental parenchymal findings detected on CT scans. There is an estimated 4%–17% prevalence of ILAs in lung cancer screening (LCS) cohorts, associated with increased all-cause mortality. A substantial proportion of fibrotic ILAs progresses to interstitial lung disease (ILD), offering an important opportunity for early identification and management of ILD. However, current reporting and management strategies for ILAs are heterogeneous, underscoring the need for standardised approaches. Objective: To explore current practice patterns among primary care physicians (PCPs), respirologists and radiologists and to assess the need for a standardised care pathway for ILAs identified through LCS programmes. Methods: Online surveys and one-on-one semistructured interviews were conducted with PCPs, respirologists and radiologists practising in Alberta, Canada. Interviews were conducted using the Theoretical Domains Framework and Consolidated Framework for Implementation Research. Survey results are presented descriptively. Qualitative data were transcribed, coded and analysed according to grounded theory principles. Results: A total of 20 PCPs and 39 respirologists completed surveys while 9 PCPs, 10 respirologists and 8 radiologists were interviewed. Sixty-one per cent of PCPs had not heard of the term ILA previously and only 13% were comfortable managing ILAs. Most respirologists (64%) did not follow a standardised approach to managing ILAs. Most PCPs and respirologists supported the development of a standardised care pathway for ILAs detected through LCS. Thematic analysis explored current knowledge and perspectives on management, clinical approach and recommendations for future directions. Barriers to a standardised pathway included heterogeneous reporting, knowledge gaps in the natural history of ILAs and healthcare resource constraints. Conclusions: This mixed-methods study provides valuable insight into the practice patterns and perceptions of PCPs, respirologists and radiologists regarding ILAs. Given the anticipated increase in ILA detection, we have conducted a needs assessment that will be foundational to building standardised care pathways for ILAs.